Exosurf Neonatal for surfactant replacement therapy
Record ID 31995000004
To address the questions of cost, efficacy and appropriateness of use of Exosurf, and to examine mortality and long-term effects; request from provincial governments.
Authors' results and conclusions: a) There is a significant reduction in mortality for infants with signs or respiratory distress, who received the drug, averaging 5.7%. Pneumothorax, BPD and PDA are also significantly reduced with rescue treatment; b) When used prophylactically, the only significant reduction seen was in mortality (6.5%); c) There are still questions that remain to be answered, including optimal dosing, the question of prophylactic versus rescue treatment, and long-term effects. Available data are not as strongly in favour of prophylaxis as they are for rescue; d) There are no cost studies on Exosurf use that have been published in Canada.
Authors' recomendations: The efficacy of the drug in reducing mortality and some other complications of RDS has been demonstrated. Further studies are necessary and are currently ongoing. It is suggested that the best and most efficient way of developing guidelines for patient selection would be through a consensus approach among the heads of tertiary level NICUs in Canada.
Authors' methods: Randomised controlled trial
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 1991
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Infant, Newborn, Diseases
- Infant, Premature, Diseases
- Intensive Care, Neonatal
- Pulmonary Surfactants
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.